Aug. 26 at 11:40 AM
There were 3 instances at end of Q2
whereby RA Capital added shares to existing positions (only 63 positions in total w
$6B AUM) — and similar biotech funds also added.
$CDTX biggest add to existing.
$10.14 -
$69.46 52 wk
There were 6 brand new starter positions for RA Capital, 4 of which were “IPO”:
HNGE- IPO May 2025
JBIO- reverse merger
OMDA - IPO June 2025
WGS- turnaround story
However 2 of the new adds have similarities (not IPO, reverse merger / SPAC), both have pending readout 2H2025 for multi
$B opptys.
$IFRX- $.71-
$2.71 -52 wk
INF904 Phase 2a for CSU and HS
RA Capital had 0 shares at Q125, but added alongside Ikarian and Adage —all 3 taking starter positions.
RA: 0 to 1,973,233
Adage: 0 to 331,133
Ikarian: 0 to 705,010
$TNGX
$1.03-
$11.97-52wk
TNG462 and TNG456 Phase 1/2
RA Capital had 0 shares at Q125, but added alongside Adage —many others taking starter positions:
RA: 0 to 2,000,000
Adage: 0 to 5,905,394
Woodline: 506,731 to 6,029,906
